Navigation Links
Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
Date:2/22/2010

ported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

                      -- Financial Statements Follow --



                JIANGBO PHARMACEUTICALS, INC. AND SUBSIDIARIES
         (FORMERLY KNOWN AS GENESIS PHARMACEUTICAL ENTERPRISES, INC.)
       CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME
     FOR THE THREE MONTHS AND SIX MONTHS ENDED DECEMBER 31, 2009 AND 2008
                                 (UNAUDITED)

                           For the Three Months Ended For the Six Months Ended
                                  December 31,               December 31,
                               2009          2008         2009        2008
    REVENUES:
      Sales                $18,179,942   $32,944,809  $42,563,996 $60,265,493
      Sales - related
       parties                      --            --           --     243,909
         Total revenues     18,179,942    32,944,809   42,563,996  60,509,402

    COST OF SALES
      Cost of sales          4,667,049     7,138,166   10,927,448  12,851,210
      Cost of sales -
       related parties              --            --           --      54,493
          Total cost of
           sales             4,667,049     7,138,166   10,927,448  12,905,703

    GROSS PROFIT            13,512,893    25,806,643   31,636,548  47,603,6
'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine technology :

1. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
2. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
3. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
4. Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
5. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... ,    ... ~   Kiadis Pharma B.V. ... biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, ... , MD PhD, as its Chief Medical Officer. ... at Ceronco Biosciences. Prior to that he was VP ...
(Date:9/2/2014)... 2014 Reportbuyer.com has added a new ... Technologies for Molecular Imaging Devices ... The objectives of this study are to ... used for diagnostic purposes, present global market measurements ... market segments as well as forecast market and ...
(Date:9/2/2014)... -- Numotion is pleased to announce the appointment of Mark ... Mark is a 30-year retired veteran of GE where ... and was a GE Company Officer since 1999 and a ... running business units within GE Healthcare, with the most recent ... "We are delighted to welcome Mark to our Board," ...
Breaking Medicine Technology:Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 2Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 3Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 4Kiadis Pharma Appoints Jeroen Rovers as its Chief Medical Officer 5Global Markets and Technologies for Molecular Imaging Devices 2Global Markets and Technologies for Molecular Imaging Devices 3Global Markets and Technologies for Molecular Imaging Devices 4Global Markets and Technologies for Molecular Imaging Devices 5Global Markets and Technologies for Molecular Imaging Devices 6Global Markets and Technologies for Molecular Imaging Devices 7Global Markets and Technologies for Molecular Imaging Devices 8Global Markets and Technologies for Molecular Imaging Devices 9Global Markets and Technologies for Molecular Imaging Devices 10Global Markets and Technologies for Molecular Imaging Devices 11Global Markets and Technologies for Molecular Imaging Devices 12Global Markets and Technologies for Molecular Imaging Devices 13Global Markets and Technologies for Molecular Imaging Devices 14Global Markets and Technologies for Molecular Imaging Devices 15Global Markets and Technologies for Molecular Imaging Devices 16Global Markets and Technologies for Molecular Imaging Devices 17Global Markets and Technologies for Molecular Imaging Devices 18Global Markets and Technologies for Molecular Imaging Devices 19Global Markets and Technologies for Molecular Imaging Devices 20Global Markets and Technologies for Molecular Imaging Devices 21Global Markets and Technologies for Molecular Imaging Devices 22Global Markets and Technologies for Molecular Imaging Devices 23Global Markets and Technologies for Molecular Imaging Devices 24Global Markets and Technologies for Molecular Imaging Devices 25
... Tenn., Nov. 18, 2011 MedSolutions , ... services, today announced the launch of its Implantable ... evidence-based guidelines to ensure the clinical appropriateness of ... With the cost of each ICD/CRT-D ...
... Md., Nov. 18, 2011 The U.S. Food and ... ) to treat patients with acute lymphoblastic leukemia (ALL), ... coli derived asparaginase and pegaspargase chemotherapy drugs used ... ) Acute lymphoblastic leukemia is a ...
Cached Medicine Technology:MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 2MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries 3FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3
(Date:9/3/2014)... CA (PRWEB) September 03, 2014 AttorneyOne.com, a ... the latest information from the FDA on Pedigree nutrition ... August 26, that 22 bags of Pedigree Adult Complete Nutrition ... the possible presence of a foreign material. The reason for ... fragments, which could have entered the packages during the production ...
(Date:9/3/2014)... An inspiring story of the importance ... the season finale of “Extreme Weight Loss” Season Four. ... daughter from Highlands Ranch, Colo. who have a strained ... pounds. Their challenge is to team up to lose ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:9/3/2014)... September 03, 2014 Pwnie Express today ... cutting edge Pwn Plug, the R3, an inconspicuous pentesting ... of use at remote locations at a fraction of ... Pwnie Express is the only company to assess wired ... Plug R3 is a next-generation penetration testing device in ...
(Date:9/3/2014)... "What can you say about a sixteen-year-old girl who ... Eight in the Margaret of Greenwich (R) Young Adult ... Books, Inc . These novels narrate the lives of a ... in America. , In this thriller, learning geometry becomes the ... student’s murder plot. Her fears increase when Erika, the only ...
(Date:9/2/2014)... dry eye disease include the sensation of grit in ... disturbance. The causes are poorly understood., The researchers base ... 87 (average age 57) from the TwinsUK cohort, drawn ... London., This cohort is widely regarded as representative of ... look at a wide range of diseases and genetic ...
Breaking Medicine News(10 mins):Health News:Pedigree Adult Complete Nutrition for Dogs Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 2Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 3Health News:Pwnie Express Releases Next Generation Penetration Testing Device: The Pwn Plug R3 4Health News:Town Locked Down After Bombing and Murders in "Margaret and Hillary" - New Book Eight in the Margaret of Greenwich(R) Young Adult Series by R. L. Rhyse 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2
... THURSDAY, March 1 (HealthDay News) -- Where a bird lives ... city dwellers tweeting at a higher pitch than those residing ... recordings, researchers from the University of Copenhagen in Denmark and ... they sing due to city buildings -- not just the ...
... megakaryocytes giant blood cells that produce wound-healing platelets manage ... The findings, to be published March 13 in the journal ... this process may cause a form of leukemia. "A failure ... megakaryoblastic leukemias," said Diane Krause, senior author of the paper, who ...
... THURSDAY, March 1 (HealthDay News) -- Scientists studying mice ... the ability to momentarily retain and utilize information needed ... the March 2 print issue of Cell , ... impairs memory by affecting passive support cells known as ...
... past few decades, doctors have noted a surprising trend ... tongue. Though oral cancer previously appeared predominantly in elderly ... it,s increasing in younger patients: 30- to 50-year-old nonsmokers ... of cancer tends to be less aggressive, and the ...
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- ... help people with the rare bone marrow disorder called myelofibrosis. ... the brand name Jakafi, won,t cure myelofibrosis, it can help ... according to the studies. "This is probably the ...
... Aging does not appear to be a factor in poor ... fact, subjective sleep quality seems to improve over a lifetime, with ... flies in the face of popular belief," said Michael Grandner, PhD, ... what we know about sleep in older people men and ...
Cached Medicine News:Health News:City Birds Sing Differently Than Their Country Cousins 2Health News:How red blood cells get so big -- and the bad things that happen when they don't 2Health News:Mayo Clinic: Robotic surgery proves successful, less invasive way to treat HPV-related oral cancer 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 3Health News:Study: Sleep gets better with age, not worse 2
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: